Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(40.0%)

N/A

1(20.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(2)

N/A(1)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06133439Not ApplicableEnrolling By Invitation

Rural Indiana Screening for Colorectal Cancer

Role: collaborator

NCT00941759Completed

Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Role: collaborator

NCT03501381Phase 2Active Not Recruiting

High Dose IL 2 and Entinostat in RCC

Role: collaborator

NCT01639248Phase 2Completed

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

Role: collaborator

NCT00005796Phase 1Completed

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Role: collaborator

NCT00313573Phase 3Unknown

Telemedicine or Standard Care in Treating Patients With Depression and/or Pain Caused By Cancer

Role: lead

All 6 trials loaded